Is Human Paraoxonase 1 the Saviour Against the Persistent Threat of Organophosphorus Nerve Agents?

被引:5
作者
Iyengar, A. R. Satvik [1 ]
Pande, Abhay H. [2 ]
机构
[1] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia
[2] NIPER, Dept Biotechnol, Sect 67, Mohali 160062, Punjab, India
关键词
Organophosphorus nerve agents; novichok agents; acetylcholinesterase; butrylcholinesterase; paraoxonase; 1; nerve agent toxicity; prophylactic; SOMAN-INDUCED SEIZURES; HUMAN BUTYRYLCHOLINESTERASE; DIRECTED EVOLUTION; HALF-LIFE; CATALYTIC BIOSCAVENGERS; IN-VIVO; PON1; EXPRESSION; PROTECTION; TOXICITY;
D O I
10.2174/0929866526666190403120259
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nerve agents have been used extensively in chemical warfare in the past. However, recent use of Novichok agents have reignited the debate on the threat posed by Organophosphorus Nerve Agents (OPNAs). The currently available therapy for OPNA toxicity is only symptomatic and is potentially ineffective in neutralizing OPNAs. Hence, there is a dire need to develop a prophylactic therapy for counteracting OPNA toxicity. In this regard, human paraoxonase 1 has emerged as the enzyme of choice. In this review, we have focussed upon the recent and past events of OPNA use, their mechanism of action and toxicity. Further, we have emphasized upon the potential of enzyme based therapy and the various advances in the development of paraoxonase 1 as a countermeasure for OPNA poisoning. Finally, we have elaborated the shortcomings of paraoxonase 1 and the work that needs to be undertaken in order to develop human paraoxonase 1 as a prophylactic against OPNA poisoning.
引用
收藏
页码:471 / 478
页数:8
相关论文
共 99 条
[1]   Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization [J].
Aharoni, A ;
Gaidukov, L ;
Yagur, S ;
Toker, L ;
Silman, I ;
Tawfik, DS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :482-487
[2]   Paraoxonase 1 (PON1) reduces macrophage inflammatory responses [J].
Aharoni, Saar ;
Aviram, Michael ;
Fuhrman, Bianca .
ATHEROSCLEROSIS, 2013, 228 (02) :353-361
[3]   FDA-approved poly(ethylene glycol)-protein conjugate drugs [J].
Alconcel, Steevens N. S. ;
Baas, Arnold S. ;
Maynard, Heather D. .
POLYMER CHEMISTRY, 2011, 2 (07) :1442-1448
[4]  
Altenbuchner J., 2005, Production of Recombinant Proteins: Novel Microbial and Eukaryotic Expression Systems, P7
[5]  
[Anonymous], 2012, ADV PREV MED, DOI DOI 10.1155/2012/507571
[6]   Effectiveness of Donepezil, Rivastigmine, and (±)Huperzine A in Counteracting the Acute Toxicity of Organophosphorus Nerve Agents: Comparison with Galantamine [J].
Aracava, Yasco ;
Pereira, Edna F. R. ;
Akkerman, Miriam ;
Adler, Michael ;
Albuquerque, Edson X. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 331 (03) :1014-1024
[7]   Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning [J].
Bajaj, Priyanka ;
Tripathy, Rajan K. ;
Aggarwal, Geetika ;
Datusalia, Ashok K. ;
Sharma, Shyam S. ;
Pande, Abhay H. .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2016, 180 (01) :165-176
[8]   Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli [J].
Bajaj, Priyanka ;
Tripathy, Rajan K. ;
Aggarwal, Geetika ;
Pande, Abhay H. .
PROTEIN EXPRESSION AND PURIFICATION, 2015, 115 :95-101
[9]  
Bajaj Priyanka, 2014, ScientificWorldJournal, V2014, P854391, DOI 10.1155/2014/854391
[10]  
Balali-Mood M, 2012, IRAN J MED SCI, V37, P74